

Ref. No: ADL/2-M/2015

Date : 30th January, 2015.

To, The Department of Corporate Services BSE Ltd., Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. BSE Code: 524348	To, The Secretary The National Stock Exchange of India Ltd., Exchange Plaza, 5 th Floor, Plot No.C/1, G Block, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051. NSE Scrip: AARTIDRUGS
--	--

Dear Sirs,

Ref.: Compliance of Clause 41 of the Listing Agreement.

Sub: Audited Financial Results for the quarter and nine month ended 31st December, 2015.

In terms of Clause 41 of the Listing Agreement, we are forwarding herewith the Audited Financial Results along with Auditor's Report on Financial Results of the Company for the quarter and nine month ended 31st December, 2014 in the prescribed form which have been taken on record by the Board of Directors of the Company at its meeting held on Friday, 30th January, 2015 at Mumbai.

Further, please note that the Company has already made necessary arrangement to publish the same in the newspapers as required under the Listing Agreement.

Please take note of the same on your record.

Thanking you,

Yours faithfully,
For **AARTI DRUGS LIMITED**



SUNNY PAGARE
COMPANY SECRETARY

Encl: as above.



Aarti Drugs Limited

Manufacturers of : Formulations, Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Plot No. 109-D, Road No. 29, Sion (East),
Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax : 022-2407 3462 / 2407 0144
Email : formulation@aartidrugs.com
Website : www.aartidrugs.com
CIN NO : L37060MH1984PLC055433

AARTI DRUGS LIMITED							
STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2014							
PART I		Quarter Ended			(Rs. in lacs except for share data)		
Sr. No.	Particulars	31st Dec 2014 (Audited)	30th Sep 2014 (Audited)	31st Dec 2013 (Audited)	For Nine Months Ended 31st Dec 2014 (Audited)	31st Dec 2013 (Audited)	Year Ended 31st March 2014 (Audited)
1	Income from Operations						
	(a) Gross Sales / Income from Operations	28,119	30,749	23,895	86,744	74,048	104,435
	Less - Excise Duty & Sales Tax	2,161	2,161	1,719	6,239	5,234	7,441
	(a) Net Sales / Income from Operations (Net Of Excise Duty & Sales Tax)	25,958	28,588	22,176	80,505	68,814	96,994
	(b) Other Operating Income	150	39	40	199	61	183
	Total income from operations (net)	26,107	28,626	22,215	80,704	68,875	97,176
2	Expenditure						
	(a) Cost of materials consumed	17,638	17,685	11,874	52,031	41,415	57,082
	(b) Purchase of stock-in-trade	1,602	2,727	1,800	7,524	6,847	8,602
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,964)	(480)	644	(4,490)	(1,814)	569
	(d) Employee benefits expense	918	917	806	2,706	2,379	3,241
	(e) Depreciation and Amortisation Expense	771	746	699	2,258	2,053	2,812
	(f) Other expenses	3,536	3,537	3,347	10,333	9,883	13,046
	Total expenses	22,500	25,131	19,170	70,356	60,561	85,351
3	Profit from Operations before Other Income, finance costs and exceptional items (1-2)	3,608	3,496	3,045	10,348	8,314	11,825
4	Other Income	64	-	-	64	-	-
5	Profit from ordinary activities before finance cost and exceptional items (3+4)	3,672	3,496	3,045	10,413	8,314	11,825
6	Finance costs (Interest)	986	944	924	2,912	2,432	3,349
7	Profit from ordinary activities after finance cost but before Exceptional Items (5-6)	2,686	2,552	2,121	7,501	5,882	8,476
8	Exceptional Items	-	-	-	-	-	-
9	Profit from Ordinary Activities before Tax (7-8)	2,686	2,552	2,121	7,501	5,882	8,476
10	Tax Expenses	411	677	705	1,626	1,997	2,397
	Provision for Taxation - Current	495	597	615	1,572	1,670	2,300
	- MAT Credit Entitlement	(31)	-	-	(52)	-	-
	- Earlier year	(153)	-	-	(153)	67	(253)
	Provision for Deferred Taxation	100	80	90	260	260	350
11	Net profit from ordinary Activities after Tax (9-10)	2,275	1,875	1,416	5,874	3,884	6,080
12	Extraordinary items	-	-	-	-	92	92
13	Net Profit for the Period (11+12)	2,275	1,875	1,416	5,874	3,976	6,171
14	Paid-up Equity Share Capital of Rs. 10/- each	1,211	1,211	1,211	1,211	1,211	1,211
15	Reserves & Surplus (excluding revaluation reserves)	-	-	-	-	-	23,880
16	Earning per share (of Rs. 10/-each) (not annualised)						
	Diluted E P S (in Rs.)						
	(a) Basic & Diluted (before extraordinary items)	18.79	15.49	11.69	48.51	32.83	50.21
	(b) Basic & Diluted (after extraordinary items)	18.79	15.49	11.69	48.51	32.83	50.97
PART II							
A PARTICULARS OF SHAREHOLDING							
1	Public shareholding						
	-Number of Shares	4,769,701	4,842,136	4,901,063	4,769,701	4,901,063	4,890,428
	-Percentage of Total Shareholding	39.39	39.99	40.48	39.39	40.48	40.39
2	Promoters & Promoter Group shareholding						
	a) Pledged/Encumbered						
	- Number of Shares	Nil	Nil	Nil	Nil	Nil	Nil
	-Percentage of shares(as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil	Nil
	-Percentage of shares(as a % of the total Share capital of the company)	Nil	Nil	Nil	Nil	Nil	Nil
	b) Non-encumbered						
	- Number of Shares	7,338,649	7,266,414	7,207,487	7,338,649	7,207,487	7,218,122
	-Percentage of shares(as a % of the total Shareholding of promoter and promoter group)	100	100	100	100	100	100
	-Percentage of shares(as a % of the total Share capital of the company)	60.61	60.01	59.52	60.61	59.52	59.61
		Qtr Ended 31st Dec. 2014					
B INVESTOR COMPLAINTS							
	Pending at the beginning of the quarter	0					
	Received during the quarter	4					
	Disposed of during the quarter	4					
	Remaining unresolved at the end of the quarter	0					

Notes :

- The above results, reviewed by the Audit Committee, have been taken on record by the Board of Directors at their meeting held on 30th January, 2015
- 2nd Interim Dividend :** The Board of Directors have declared a 2nd Interim Dividend of Rs. 5/- per Equity shares of Rs.10/- each amounting to Rs. 8,05,42,750/- and 5th February, 2015 has been fixed as record date for payment of said 2nd interim dividend.
- Announcement of Bonus Shares :** The Board of Directors have announced issue of 121,08,550 bonus equity shares by capitalization of reserves and surplus including securities premium account in proportion of 1:1 i.e. 1(One) equity share of Rs. 10 each fully paid up for every existing 1(one) equity share of Rs.10 each Fully paid up held by the shareholders on the 'Record Date' subject to approval by the members of the company. 'Record Date' for issue of bonus shares will be fixed after approval of bonus issue by the shareholders through Postal Ballot and E-Voting.
- Company is operating as a Single Segment Company, engaged in Pharmaceuticals Business.
- Figures for the previous period have been regrouped or rearranged wherever necessary.

Place : Mumbai
Date : 30th January, 2015.

For and on behalf of the Board
For AARTI DRUGS LIMITED

HARSHIT M. SAVLA
(JT. MANAGING DIRECTOR)



gokhale & sathe (regd.)
chartered accountants
308/309, Udyog Mandir No. 1,
7-C, Bhagoji Keer Marg,
Mahim, Mumbai 400 016

Auditors' Report on Quarterly Financial Results and Year to Date Results of
AARTI DRUGS LTD Pursuant to the Clause 41 of the Listing Agreement

To

Board of Directors of AARTI DRUGS LTD

We have audited the quarterly financial results of AARTI DRUGS LTD for the quarter ended 31st December 2014, and the year to date results for the period from 1st April 2014 to 31st December 2014 attached herewith, being submitted by the company pursuant to the requirement of clause 41 of the Listing Agreement except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25 on Interim Financial Reporting issued under the Companies (Accounting Standard Rules) 2006 which continue to apply under section 133 of the Companies Act 2013 and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.





In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results:

- (i) are presented in accordance with the requirements of clause 41 of the Listing Agreement in this regard; and
- (ii) give a true and fair view of the net profit and other financial information for the quarter ended 31st December 2014 and the year to date results for the period from 1st April 2014 to 31st December 2014.

Further, we also report that we have, on the basis of the books of account and other records and information and explanations given to us by the management, also verified the number of shares as well as percentage of shareholdings in respect of aggregate amount of public shareholdings, as furnished by the company in terms of clause 35 of the Listing Agreement and found the same to be correct.

For GOKHALE & SATHE
CHARTERED ACCOUNTANTS
Firm Registration No: 103264W

CA. TEJAS. J. PARIKH
PARTNER
Membership No. 123215
Mumbai, Dated: January 30, 2015





Aarti Drugs Limited

Manufacturers of : Formulations, Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Plot No. 109-D, Road No. 29, Sion (East),
Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax : 022-2407 3462 / 2407 0144
Email : formulation@aartidrugs.com
Website : www.aartidrugs.com
CIN NO : L37060MH1984PLC055433

Ref. No.: ADL/SE/2-M/2015
Date: 30th January, 2015

To,
The Department of Corporate Services
BSE Ltd.
Phiroze Jeejeebhoy Towers,
Dalal Street,
MUMBAI – 400 001.
BSE CODE –524348

To,
National Stock Exchange of India Limited
“Exchange Plaza”,
Bandra - Kurla Complex, Bandra(E),
Mumbai – 400 051
NSE CODE: AARTIDRUGS

Dear Sirs,

Sub: Compliance of Clause 20(a) of the Listing Agreement.

In terms of Clause 20(a) of the Listing Agreement, we wish to inform you that the Board of Directors of the Company at its meeting held on Friday, 30th January, 2015 has declared 2nd Interim dividend @ Rs. 5.00 ps. per share for the financial year 2014-2015.

The details of the dividend payable will be as under:

	Amount (Rs.)
2 nd Interim Dividend of Rs. 5.00 ps per share on 12108550 Equity Shares of Rs.10/- each fully paid up	60542750 /-

Please note that as per the clause 16 of the Listing Agreement, Monday, 5th February, 2015 has been fixed as record date for the purpose of payment of Interim Dividend and the same has already been intimated to the stock exchanges. It is further intimated that the aforesaid 2nd Interim Dividend will be dispatch to registered members of the Company on 10th February, 2015.

Kindly take the note of the above.

Thanking you,

Yours faithfully,
For **AARTI DRUGS LIMITED**

HARSHIT M. SAVLA
JT. MANAGING DIRECTOR